Cargando…

Development and Validation Features of the Patient Benefit Index for the Treatment of Allergic Rhinoconjunctivitis with Allergen Immunotherapy

PURPOSE: Allergic rhinoconjunctivitis (ARC) is one of the most common diseases worldwide. Allergen immunotherapy (AIT) is the only causal treatment available so far. Due to health policy provisions, the assessment of treatment benefit from the patient’s perspective is of high relevance. To date, no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Langenbruch, Anna, Wüstenberg, Eike, Wolf, Hendrik, Augustin, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109726/ https://www.ncbi.nlm.nih.gov/pubmed/35586793 http://dx.doi.org/10.2147/JAA.S357469

Ejemplares similares

Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review
por: Dhami, Sangeeta, et al.
Publicado: (2016)

Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis
por: Penagos, Martin, et al.
Publicado: (2018)

Erratum to: Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review
por: Dhami, Sangeeta, et al.
Publicado: (2017)

Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews
por: Nurmatov, Ulugbek, et al.
Publicado: (2017)

Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany
por: Verheggen, Bram G, et al.
Publicado: (2015)

Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis
por: Devillier, Philippe, et al.
Publicado: (2014)

Pollen aero allergens and the climate in mediterranean region and allergen sensitivity in allergic rhinoconjunctivitis and allergic asthma patients
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Allergic rhinoconjunctivitis
por: Miraglia del Giudice, Michele, et al.
Publicado: (2020)

233 The Evaluation of Allergen Sensitivity in Allergic Rhinoconjunctivitis and Allergic Asthma Patients in Antalya, Turkey
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis
por: Kim, Harold, et al.
Publicado: (2014)

Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy
por: Poole, Chris D, et al.
Publicado: (2014)

Allergic Rhinoconjunctivitis: the Role of Histamine
por: Andersson, M., et al.
Publicado: (1994)

Bilastine for allergic rhinoconjunctivitis, urticaria
Publicado: (2022)

A meta‐analysis on allergen‐specific immunotherapy using MCT(®) (MicroCrystalline Tyrosine)‐adsorbed allergoids in pollen allergic patients suffering from allergic rhinoconjunctivitis
por: Becker, Sven, et al.
Publicado: (2021)

Randomized controlled trial of ragweed sublingual immunotherapy tablet in the subpopulation of Canadian children and adolescents with allergic rhinoconjunctivitis
por: Ellis, Anne K., et al.
Publicado: (2021)

The effects of climate and aero allergens changes in allergic rhinoconjunctivitis and allergic asthma patients in mediterranean region between 2011 and 2012
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

“The value of pre- and co-seasonal sublingual immunotherapy in pollen-induced allergic rhinoconjunctivitis”
por: Demoly, Pascal, et al.
Publicado: (2015)

161 Efficacy and Safety of 300IR 5-Grass Pollen Sublingual Allergen Immunotherapy Tablets in us Adults With Grass-Pollen Allergic Rhinoconjunctivitis
por: Cox, Linda, et al.
Publicado: (2012)

A practical guide to prescribing sublingual immunotherapy tablets in North America for pediatric allergic rhinoconjunctivitis: an injection-free allergy immunotherapy option
por: Blaiss, Michael, et al.
Publicado: (2023)

Relationship between allergic rhinitis and allergic conjunctivitis (allergic rhinoconjunctivitis) - review
por: Iordache, Andreea, et al.
Publicado: (2022)

Tolerability of an Immunologically Enhanced Subcutaneous Immunotherapy Preparation in Patients Treated with Concomitant Allergy Immunotherapy: A Non-Interventional Observational Study
por: Reiber, Rainer, et al.
Publicado: (2017)

Allergic rhinoconjunctivitis: pathophysiological mechanism and new therapeutic approach
por: Ciprandi, Giorgio, et al.
Publicado: (2020)

Relevant Patient Benefit of Sublingual Immunotherapy with Birch Pollen Allergen Extract in Allergic Rhinitis: An Open, Prospective, Non-Interventional Study
por: Blome, Christine, et al.
Publicado: (2020)

Minimization of ragweed allergy immunotherapy costs through use of the sublingual immunotherapy tablet in Canadian children with allergic rhinoconjunctivitis
por: Ellis, Anne K., et al.
Publicado: (2023)

Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis
por: Rønborg, Steen M, et al.
Publicado: (2012)

Iodixanol nasal solution reduces allergic rhinoconjunctivitis signs and symptoms in Allergen BioCube(®): a randomized clinical trial
por: Gomes, Paul J, et al.
Publicado: (2019)

Differences in allergen‐specific basophil activation and T cell proliferation in atopic dermatitis patients with comorbid allergic rhinoconjunctivitis treated with a monoclonal anti‐IL‐4Rα antibody or allergen‐specific immunotherapy
por: Layritz, Anne‐Sophie, et al.
Publicado: (2023)

Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria
por: Sadaba, Belen, et al.
Publicado: (2013)

Complementary treatment of allergic rhinoconjunctivitis: the role of the nutraceutical Lertal®
por: Marseglia, Gianluigi, et al.
Publicado: (2020)

Clinical presentation at the onset of COVID-19 and allergic rhinoconjunctivitis
por: Ferreli, Fabio, et al.
Publicado: (2020)

Evaluation of safety and tolerability of a rush up-dosing allergen-specific immunotherapy with grass pollen, birch, hazel, and alder allergoid in children with allergic rhinoconjunctivitis, with or without asthma
por: Traina, Giovanni Maria, et al.
Publicado: (2021)

Efficacy of Timothy grass allergy immunotherapy tablet (AIT) treatment in Canadian children and adults with grass pollen-induced allergic rhinoconjunctivitis (ARC)
por: Hebert, Jacques, et al.
Publicado: (2011)

Mechanisms of Allergen Immunotherapy in Allergic Rhinitis
por: Drazdauskaitė, Gabija, et al.
Publicado: (2020)

Allergic asthma: An indication for allergen immunotherapy
por: Ankermann, Tobias, et al.
Publicado: (2023)

Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study
por: Reiber, Rainer, et al.
Publicado: (2016)

Real‐world benefits of allergen immunotherapy for birch pollen‐associated allergic rhinitis and asthma
por: Wahn, Ulrich, et al.
Publicado: (2018)

Long-term benefit after allergen immunotherapy to HDM in elderly patients with allergic rhinitis
por: Bożek, Andrzej, et al.
Publicado: (2023)

Treatment of allergic rhinoconjunctivitis: a review of the role of topical levocabastine
por: Wijk, R. Gerth van
Publicado: (1995)

Efficacy of mometasone furoate and fluticasone furoate on persistent allergic rhinoconjunctivitis
por: Aneeza, W. Hamizan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fmqpmtpvhr79142e5cah9iu99d